Lasting Effect Consumer Pharma
A buccal adhesive extended-release tablet bypassing the first pass delivery route
Startup Pre-Seed Est. 2020
Total Raised
$1.85M
Pre-Seed
Last Round
$850K
2 rounds
Investors
3
3 public
Team
4
1-10 employees
Confidence
80/100
Patents
1
About
Lasting Effect developed a Buccal extended controlled release delivery system. The system is a platform enables topical effect or systemic absorption of active ingredients through transmucosal and sublingual routes, Bypassing first-pass metabolism and offers a greater bioavailability, while maintaining user’s compliance during both wakefulness and sleeping hours. The technology based on patented extended controlled release mechanism, combined with selected taste compounds that generates saliva. Lasting Effect drug delivery system is a platform enables topical effect or systemic absorption of active ingredients through transmucosal route, offers a greater bioavailability, while maintaining user’s compliance during both wakefulness and sleeping hours. The technology based on patented extended controlled release system, combined with selected taste compounds that generates saliva. The saliva dissolves the tablet and the active material loaded on it. The technology enables to load and dissolve a wide range of active materials, including lipophile hydrophobic materials. The platform tablet adhered to the mucosa in the oral cavity, laniary dissolving for up to 8 hours while screening bitter tastes of the active materials. All the inactive materials of the platform are GRAS. Products: 1. Buccal tablet for Xerostomia and Halitosis. Regulation as dietary supplement. Ready to market. 2. Tablet loaded with CBD for Gingivitis - gum inflammation, treatment. The product is in a clinical stage. The tablet loaded with CBD shown a powerful anti-inflammatory effect, inhibiting between 93-96% of Gingivitis causing bacteria's. 3. In development - tablet for Parkinson and cognitive impairments treatment. Unique formulation of antiparkinsonian drugs, which is loaded into the tablet and releases continuously the APIs in the oral cavity, enabling to provide a continues dopaminergic stimulation. Partners: Maccabi HealthCare, Padagis Pharma, OwerCrowd, Kobi Zaharia, Ariel Malik.
Classification
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrug Delivery
Target Customer
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business Model
B2B2C
Tags
healthcareparkinsondrug-deliverymedical-cannabispharma-companiespharmaceuticals
Funding & Events
Jan 2023
Pre-Seed $1M
MaccabiDent, OurCrowd, Padagis
Jan 2023
Non-equity $850K
Israel Innovation Authority
Details
Product Stage
Clinical Trial
Employees
1-10
Exact Count
7
District
South District
Founded
2020
Registrar
516174455
Locations
Be'er Sheva, Israel
Links
Website
LinkedIn
Admin
Last Update
Sep 5, 2025
Verified by
Yanina Wainscheinker
Claimed
Yes
Missing
sector, news, markets, not claimed
Team (4)
David Tavor
Board member, Investors relations
Founder
Igal Pikovsky
CEO
Founder
Eli Heldman
CTO
Founder
Igal Pikovsky
Internal
Created by
Igal Pikovsky (igal@lasting-effect.com)
Created
2023-08-21T00:00:00.000Z